Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Monopar Therapeutics changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 10 | 10 | 0 |
| Shares | 199.1K | 198.7K | −398 (−0.2%) |
| Value | $314.0K | $471.0K | +$157.0K (+50.0%) |
New holders (2)
Institutions that held Monopar Therapeutics at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rappaport Reiches Capital Management, LLC | 10,695 | $25.3K | 0.01% |
| Bank of America Corp | 10 | $24 | 0.00% |
Sold out (2)
Institutions that held Monopar Therapeutics at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Susquehanna International Group, LLP | 10,584 | $16.0K |
| IFP Advisors, Inc | 500 | $13.0K |